Significant drug-drug interactions with antineoplastics

Hospital Pharmacy

Volumn 35, Issue 11, 2000, Pages 1207-1220

  May, S K ^a  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

Author keywords

Antineoplastic agents; Chemotherapy; Drug interactions; Drug therapy

Indexed keywords

ALKYLATING AGENT; ALLOPURINOL; ANTIESTROGEN; ANTIMETABOLITE; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOSPORIN; EPIPODOPHYLLOTOXIN; ERYTHROMYCIN; ESTROGEN DERIVATIVE; ETOPOSIDE; FLUOROURACIL; FOLIC ACID ANTAGONIST; HORMONE; ITRACONAZOLE; LOOP DIURETIC AGENT; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; MITOMYCIN; NITROSOUREA DERIVATIVE; PURINE ANTAGONIST; PYRIMIDINE ANTAGONIST; UNINDEXED DRUG; VACCINE; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG ABSORPTION; DRUG ELIMINATION; DRUG INCOMPATIBILITY; DRUG METABOLISM; DRUG PROTEIN BINDING; HIGH RISK PATIENT; HUMAN; OTOTOXICITY; PHARMACIST; REVIEW;

EID: 0033730078     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870003501107     Document Type: Review

References (59)

1. Drug-related morbidity and mortality: A cost-of-illness model
2. Adverse drug events in hospitalized patients: Excess length of stay, extra costs, and attributable mortality
3. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group
4. Drug interactions in the oncology patient
5. Interactions and drug-metabolizing enzymes
6. Update: Clinically significant cytochrome P450 drug interactions
7. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature
8. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes
9. Pharmacokinetics of the novel antiestrogenic agent toremifene in subjects with altered liver and kidney function
10. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma
11. The effect of organic acids on renal clearance of methotrexate in man
12. Aspirin alters methotrexate disposition in rheumatoid arthritis patients
13. Clinical and pharmacokinetic evidence of life-threatening interaction between methotrexate and ketoprofen
14. Methotrexate and non-steroidal antiinflammatory drug interactions
15. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam, and flurbiprofen in patients with rheumatoid arthritis
16. The effects of salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis
17. Acute renal failure due to concomitant action of methotrexate and indomethacin
18. Acute nephrotic syndrome with reversible renal failure after phenylbutazone
19. Methotrexate-nonsteroidal antiinflammatory drug interaction in children with arthritis
20. Methotrexate-related deaths in patients previously treated with cis-diamminedichloride platinum
21. The intrapatient effect of cisplatin therapy on the pharmacokinetics of high-dose methotrexate
22. Hepatotoxicity of long-term methotrexate therapy
23. Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients
24. Pharmacokinetic interaction between high-dose methotrexate and amoxicillin
25. Clinical pharmacology of oral intermediate-dose methotrexate with or without probenecid
26. Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia
27. Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol
28. Azathioprine and allopurinol: The price of an avoidable drug interaction
29. 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer
30. Vinblastine and erythromycin: An unrecognized serious drug interaction
31. Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin
32. Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma
33. Severe vincristine toxicity in combination with itraconazole
34. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL
35. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
36. High-dose cyclosporin with etoposide - Toxicity and pharmacokinetic interaction in children with solid tumors
37. Potentiating effects of cisplatin and ethacrynic acid in ototoxicity
38. Bone-marrow depression with cimetidine plus carmustine
39. Potentiation of carmustine-cranial irradiation-induced myelosuppression by cimetidine
40. N-isopropyl-a-(2-methylhydrazino)-p-toluamide, hydrochloride (NSC-77213) in treatment of solid tumors
41. Natulan in the management of late Hodgkin's disease, other lymphoreticular neoplasms, and malignant melanoma
42. The mechanism of alcohol intolerance produced by various therapeutic agents
43. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide
44. Life threatening interaction between tamoxifen and warfarin
45. Tamoxifen-warfarin interaction: The Aberdeen hospital drug file
46. Life threatening interaction between tamoxifen and warfarin
47. Mitotane spironolactone antagonism in Cushing's syndrome
48. Use of vaccines and immune globulins in persons with altered immunocompetence: Recommendations of the Advisory Committee on Immunization Practices (ACIP)